Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

Immunic, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK , NOV. 26, 2025 /PRNEWSWIRE/ -- IMMUNIC, INC. (NASDAQ: IMUX),A LATE-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF NOVEL ORAL THERAPIES FOR NEUROLOGIC AND GASTROINTESTINAL DISEASES, TODAY ANNOUNCEDTHAT DANIEL VITT, PH.D., CHIEF EXECUTIVE OFFICER OF IMMUNIC, WILL PARTICIPATE IN A FIRESIDE CHAT ON THURSDAY, DECEMBER 4, 2025 AT 9:35 AM ET AT THE 8TH ANNUAL EVERCORE ISI HEALTHCARE CONFERENCE, TAKING PLACE DECEMBER 2-4, 2025 IN CORAL GABLES, FL.

IMMUNIC TO PARTICIPATE IN THE 8TH ANNUAL EVERCORE ISI HEALTHCARE CONFERENCE IN DECEMBER

 KEY DATA HIGHLIGHTING VIDOFLUDIMUS CALCIUM'S THERAPEUTIC POTENTIAL IN MULTIPLE SCLEROSIS PRESENTED AT 41ST CONGRESS OF ECTRIMS   PHASE 2 CALLIPER DATA DEMONSTRATED STATISTICALLY SIGNIFICANT 24-WEEK CONFIRMED DISABILITY IMPROVEMENT IN PROGRESSIVE MULTIPLE SCLEROSIS, WITH CONSISTENT SIGNALS FOR SLOWING DISABILITY PROGRESSION ACROSS SUBGROUPS AND ENDPOINTS, SUPPORTING VIDOFLUDIMUS CALCIUM'S NEUROPROTECTIVE POTENTIAL AND NURR1 ACTIVATION MECHANISM   LONG-TERM PHASE 2 EMPHASIS DATA IN RELAPSING-REMITTING MULTIPLE SCLEROSIS SHOWED HIGH RATES OF PATIENTS REMAINING FREE OF CONFIRMED DISABILITY WORSENING AND FAVORABLE LONG-TERM SAFETY AND TOLERABILITY   TOP-LINE DATA FROM TWIN PHASE 3 ENSURE TRIALS OF VIDOFLUDIMUS CALCIUM IN RELAPSING MULTIPLE SCLEROSIS EXPECTED BY YEAR-END 2026  NEW YORK , NOV. 13, 2025 /PRNEWSWIRE/ -- IMMUNIC, INC. (NASDAQ: IMUX),A LATE-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF NOVEL ORAL THERAPIES FOR NEUROLOGIC AND GASTROINTESTINAL DISEASES, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025, AND PROVIDED A CORPORATE UPDATE. "THE THIRD QUARTER WAS MARKED BY OUR STRONG PRESENCE AT THE 41ST CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS), DURING WHICH WE HAD THE OPPORTUNITY TO HIGHLIGHT THE CLINICAL MOMENTUM OF OUR LEAD ASSET, VIDOFLUDIMUS CALCIUM (IMU-838), AN ORALLY AVAILABLE NUCLEAR RECEPTOR-RELATED 1 (NURR1) ACTIVATOR, AND ITS POTENTIAL TO TRANSFORM THE ORAL MULTIPLE SCLEROSIS (MS) THERAPY LANDSCAPE," STATED DANIEL VITT, PH.D.

IMMUNIC, INC. REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

NEW YORK , OCT. 29, 2025 /PRNEWSWIRE/ -- IMMUNIC, INC. (NASDAQ: IMUX),A BIOTECHNOLOGY COMPANY DEVELOPING A CLINICAL PIPELINE OF ORALLY ADMINISTERED, SMALL MOLECULE THERAPIES FOR CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED PARTICIPATION IN THE FOLLOWING INDUSTRY AND INVESTOR CONFERENCES IN NOVEMBER: NOVEMBER 3-5:BIO-EUROPE. DANIEL VITT, PH.D.

Immunic, Inc.

IMUX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Immunic, Inc.

IMUX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IMUX